---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019095"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:39:11.029664+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency

## Summary
- Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.
- Nasdaq notified company on Oct 22 of bid-price non-compliance (closing price <$1 for 30 days); no grace period due to prior reverse split.
- Company received $2.2M gross from warrant exercises in September to raise stockholders' equity above $2.5M minimum.
- Company intends to request a hearing to appeal delisting; no assurance of continued listing.
- Warrants issued in the inducement become exercisable only after stockholder approval per Nasdaq Rule 5635(d).

## SEC filing metadata
- accession: 0001493152-25-019095
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/0001493152-25-019095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019095
- JSON: https://secwatch.observer/filing/0001493152-25-019095.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019095.txt

## Source-grounded claims
- claim_id: 624e55caf111d71711bbed418e3e534e9c8e2617
  claim: Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: the “Company”) received a notice from The Nasdaq Stock Market (the “Nasdaq”) indicating that it no longer met the continued listing requirements. Specifically, the Company’s stockholders’ equity was below the minimum required stockholders’ equity of $2.5 million as stipulated by Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). As noted in the Original 8-K, the Company had until October 10, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on October 10, 2025. The Company is filing this Current Report on Form 8-
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/0001493152-25-019095-index.htm
- claim_id: 6349fdfd80b241e19440b9b5ebd2f5c6a78216b0
  claim: Enveric Biosciences, Inc.: Certificate of Amendment filed to effect 1-for-12 reverse stock split of common stock (effective 2025-10-28).
  evidence_excerpt: On October 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-12 reverse stock split of the shares of the Company’s Common Stock, either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on October 28, 2025 (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/0001493152-25-019095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.